A bipartisan US congressional biotech commission is using its final weeks to warn lawmakers about licensing and deal flow with China peers, arguing that the country risks overdependence that could expose patients to supply chain weaponization. The panel is framing the issue as a competitiveness and national-security concern rather than a standard commercial negotiation. The commission’s push highlights how policy scrutiny is increasingly targeting upstream dependencies—particularly for critical biologics inputs, manufacturing capacity, and technology transfer. It also adds to the broader regulatory atmosphere affecting cross-border partnering and technology licensing decisions across the pharma and biotech ecosystem. For companies negotiating China-linked licensing, the message is clear: governance and national-security considerations may increasingly shape transaction timing, scope, and contractual safeguards. That could accelerate restructuring of development partnerships and diversify counterparties. (Story context: the warning is tied to the commission’s broader mandate on US biotech competitiveness.)